NMPA approves TABOSUN + TYVYT combo for the neoadjuvant treatment of patients with stage IIB-III resectable MSI-H/dMMR colon cancer January 4, 2026
Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic CRC Announced December 22, 2025
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch Ph 2a dose-expansion trial with TTX-MC138 December 15, 2025
Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need November 24, 2025
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology November 18, 2025
First Patient Dosed in Randomized Dose Optimization Cohort of Ph 2 Study of Muzastotug + KEYTRUDA in MSS-CRC November 10, 2025
Positive Topline Results from Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Reported and Updates Provided on CRC and Ewing Sarcoma Expansion Cohorts October 29, 2025
Interim Petosemtamab Data in Metastatic CRC Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety October 29, 2025
Positive Ph 2 Results for HBM4003 and Tislelizumab Combination in MSS mCRC announced October 29, 2025
Hansoh Pharma signs a licence agreement worth up to $1.45B with Roche for an investigational treatment of CRC and other solid tumours October 21, 2025
First patients enrolled in Ph 1 trial with KQB548 (BAY 3771249) in KRAS G12D-mutated tumors October 21, 2025
Ivonescimab Global Ph 3 Development Program with HARMONi-GI3 Study expanded in 1L CRC October 21, 2025
FDA Fast Track Designation for NG-350A for the Treatment of MMR-Proficient Locally Advanced Rectal Cancer October 18, 2025
Ph 2 study of BND-22 (SAR444881) + anti-PD-1 therapy in IO-refractory NSCLC or IO-naive MSS-CRC or ovarian cancer to be initiated October 16, 2025
Trogenix announces £70M/$95M Series A financing to drive clinical development of potentially curative therapies for aggressive cancers October 7, 2025
Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic October 7, 2025
Pidnarulex (CX-5461) + Cemiplimab (Libtayo®) combo to be tested in Ph 1/2 clinical trial for MSS CRC patients September 23, 2025
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked ADC September 23, 2025
Bayer and Kumquat Biosciences enter global exclusive license and collaboration in precision oncology September 16, 2025
